Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of vepdegestrant variant tablet in healthy adults
NCT06645938Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vepdegestrant in breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 168 hours and Area Under the Curve From Time Zero to Extrapolated Infinite Time at 168 hours. Started Oct 2024; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06645938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645938.